生物医药

Search documents
第十七届苏州国际精英创业周圆满收官
Su Zhou Ri Bao· 2025-07-15 00:08
Group 1 - The 2025 Suzhou International Elite Entrepreneurship Week attracted a total of 2,388 intended cooperation projects, including 2,267 entrepreneurial investment projects and 121 innovation cooperation projects [1] - The proportion of high-end equipment projects reached 19.4%, new generation information technology projects accounted for 18.5%, new materials represented 11.9%, software and information services made up 9.9%, and new energy projects constituted 6.2% [1] - The event facilitated the gathering of high-level talent and contributed to the construction of the "1030" industrial system in Suzhou [1] Group 2 - The event featured a 4,000 square meter exhibition showcasing over 1,300 technological achievements from 24 universities and 41 enterprises, attracting more than 4,200 visitors [2] - The first "Chunhui Innovation Training Camp" was held, attracting over a hundred overseas talents for offline engagement [2] - The 2025 Sino-foreign Academician Frontier Technology Forum included over 30 top academicians and 60 leading scholars in AI and interdisciplinary fields discussing research paradigm shifts and technological innovation paths driven by AI [2] Group 3 - The main opening ceremony of the Entrepreneurship Week was combined with the University Technology Transfer and Transformation Conference and the Second Suzhou International Science and Technology Innovation Conference [3] - The establishment of the "Billion Talent Fund" was announced, with sub-funds focusing on artificial intelligence, low-altitude economy, biomedicine, cultural creativity, and youth entrepreneurship [3] - Three "AI+" work platforms were launched to assist talent in job searching, policy matching, and service access [3]
中原有城“势”已成——写在中原医学科学城建设两周年之际
He Nan Ri Bao· 2025-07-14 23:40
2023年7月15日,省委、省政府站位高远、前瞻谋局,重建河南省医学科学院、一体打造中原医学科学 城(以下简称"中原医科城"),拉开了中原医科城建设的大幕。 两年建设发展,中原医科城"城"势而上,聚变升级。 集聚之势澎湃——顶尖科研机构、高端医疗企业、一流创新人才加速汇聚,形成生物医药与健康产业 的"强磁场"。 协同之势强劲——产学研医深度融合,基础研究、临床转化、产业应用全链条贯通,创新生态活力迸 发。 领先之势凸显——突破关键技术、抢占行业高地,在基因治疗、智能医疗、新药研发等领域引领风向。 三"势"联动,一座辐射全国、面向全球的医学创新标杆之城,正以澎湃动能在郑州航空港经济综合实验 区这片热土强势崛起! 集聚之势"加速度" 将一组血液样本无序放入设备,只需轻轻按键,便可实现自动分类、自动检测、自动生成数据……华润 医学诊断技术(河南)有限公司全自动实验室流水线"威力"大,可开展肿瘤早筛等2000余项检测项目, 日检测能力达万份样本。 政策集聚、数据集聚、成果集聚……2024年9月,在第41届全国医药工业信息年会上,中原医科城荣获 全国"最具投资潜力的生物医药大健康产业新城"称号——随着龙头企业、领军人物 ...
上海市工商联举办媒体采风活动 解码松江创新创业生态
Zhong Guo Xin Wen Wang· 2025-07-14 21:00
活动现场,上海市工商联发布了2025年度创新创业专题宣传片。宣传片通过"点亮梦想、学成归国、厚 积薄发、扬帆出海"四个篇章,呈现上海创新创业生态,突出营商环境优势,展示城市魅力。 采风活动通过走访参观与座谈交流相结合的方式,呈现松江经开区在优化营商环境、赋能民营经济中的 创新实践。上海市工商联党组成员、副主席汪剑明,松江区委常委、统战部部长朱大章,松江区委常 委、宣传部部长顾建斌参加活动。 中新网上海7月14日电(范宇斌)近日,2025年度上海市工商联媒体采风活动在上海市松江经开区正泰智 电港举行。该活动以"双向奔赴的创新创业生态"为主题,旨在搭建媒体与民营企业对接桥梁,发掘优秀 企业典型,进一步营造全社会关心、支持、促进民营经济发展的良好氛围。 松江区委统战部副部长、松江区工商联党组书记沈伟表示,作为上海高端制造业主阵地和科创中心重要 承载区,松江区坚持以开放的姿态拥抱创新、以务实的举措赋能创业。 在企业交流环节,正泰智电港、上海世纪利通、尼信电子、强昕鼎益、快思瑞科技、泰氢晨能源、睿速 创生医疗、睿植康医疗等企业代表分享了在松江的创业故事与深刻感悟。(完) (文章来源:中国新闻网) 活动现场。范宇斌摄 采 ...
创投市场频现“A+++”
Shang Hai Zheng Quan Bao· 2025-07-14 18:29
近日,浦东创投集团参与完成上海恩凯细胞技术有限公司(简称"恩凯赛药")A+++轮融资。恩凯赛药 募集资金将用于推进核心产品临床试验及新产品管线开发,加速NK细胞药物临床转化。 ◎记者 邓贞 谭镕 上海证券报记者梳理发现,创投市场近年频现"+++"甚至"++++""+++++"轮次,集中出现在半导体、生 物医药、具身智能、低空经济等赛道。部分创业企业难以一次性满足下一轮融资门槛,技术研发与商业 化验证周期长,遂通过多次"+轮"融资延长发展周期;同时,一级市场估值推高迹象明显,机构出手谨 慎却不愿错失好项目,于是以"小步快跑"方式完成融资。 在受访专家看来,"+轮"密集出现,意味着企业原本完整的一轮融资被拆分为两次甚至多次完成,融资 周期被动拉长。 机构出手谨慎 对于这些获得市场青睐的创业企业而言,原本拿一笔钱就能走完一个阶段的周期,为何如今却需要多次 融资? 茹华杰介绍,按照以往对融资轮次的界定,A、B、C、D轮标准明确,代表着企业不同的发展阶段。不 同轮次间往往代表着里程碑式事件的达成,并且在估值逻辑和估值水平上有显著差异。 "++轮"融资扎堆 近两年,Pre-A+、A+、A++、B+、B++等案例屡见不鲜。 ...
香港发出首个正式的士车队牌照;深圳私募创投在投本金超9700亿元丨大湾区财经早参
Mei Ri Jing Ji Xin Wen· 2025-07-14 17:15
Group 1: Investment and Financial Trends - As of the end of April this year, Shenzhen's private equity and venture capital funds have invested in 20,400 projects, targeting 12,500 companies nationwide, with a total investment amount of 970.275 billion yuan, showing a year-on-year increase of over 2% in early-stage, small, and hard technology projects [1] - The number of projects directed towards early-stage technology companies and the corresponding investment amount have increased by 3.89% and 3.93% year-on-year, respectively [1] Group 2: Transportation and Technology Innovations - The Hong Kong government has issued its first official taxi fleet license to Star Taxi Service Company for a period of five years, allowing the fleet to provide ride-hailing services [2] - This initiative is part of a series of measures by the Hong Kong government to optimize taxi services, aiming to establish a professional and technology-driven fleet management system [2] Group 3: Healthcare and Pharmaceutical Developments - A hospital in Shenzhen has become the first in the city to prescribe domestically developed weight-loss drugs, Ma Shidu and Te Erbo, which significantly enhance weight loss effects, especially for patients with stubborn obesity [3] - The introduction of these drugs reflects the advancement of China's biopharmaceutical industry's independent innovation capabilities and Shenzhen's pioneering efforts in medical technology applications [3] Group 4: Scientific Research and Development - China's first ocean-class intelligent research vessel, "Tongji," has been officially delivered, marking a significant advancement in marine research capabilities [4] - The vessel, which began construction in April 2024, is a 2,000-ton intelligent comprehensive research ship that will facilitate the transition from basic research to the integration of science and technology [4] Group 5: Market Performance - On July 14, the Shenzhen Composite Index closed at 10,684.52 points, down 0.11% [5] - Notable gainers in the Shenzhen market included Changrong Co. at 9.05 yuan with a rise of 20.03%, and Xinling Electric at 42.13 yuan with a rise of 19.99% [6] - Conversely, leading decliners included Yuandao Communication at 21.60 yuan, down 20.00%, and *ST Zitian at 3.52 yuan, down 17.76% [6]
培育企业蓬勃生长的沃土——加快建设全国统一大市场一线观察之八
Xin Hua Wang· 2025-07-14 14:53
Group 1 - The construction of a national unified market is a significant decision made by the central government to promote high-quality development and a new development pattern [1] - Various regions and departments are implementing measures to strengthen the foundation, address shortcomings, and remove obstacles to accelerate the establishment of an efficient, fair, and open national unified market [1][3] - The reduction of market access negative lists from 151 to 106 items, representing a decrease of approximately 30%, indicates a commitment to enhancing market vitality [3] Group 2 - The participation of private capital in nuclear power projects has increased, with ownership stakes rising from 2% in 2020 to 10% and even 20% in some projects, reflecting the effective removal of market entry barriers [2] - The number of newly established foreign-invested enterprises in China increased by 10.4% year-on-year in the first five months of the year, demonstrating China's attractiveness as a destination for foreign investment [3] Group 3 - The implementation of fair competition measures has led to a 5 percentage point increase in the bidding success rate for private enterprises, with over 80% of projects under 10 million yuan awarded to private companies [4] - The establishment of the "credit loan" product under the "Xin Yi Dai" platform has enabled small and medium-sized enterprises to secure loans more easily, with approximately 5.5 million enterprises registered for financing needs through the national integrated credit service platform [6] Group 4 - The logistics efficiency has improved significantly, with innovations in regulatory models allowing for faster delivery times, such as milk reaching consumers in just 72 hours [7] - The rise of e-commerce platforms has enabled regional specialty products, like prickly pear juice, to thrive in the national market, showcasing the transformation of local products into billion-dollar industries [8] Group 5 - The commercial aerospace sector is experiencing rapid growth, with the number of supply chain partners expanding from over 100 in 2018 to more than 1,300, driven by favorable market conditions and collaborative opportunities [10] - The integration of digital platforms in supply chain management is enhancing resilience and security across various industries, allowing for equal participation from all types of enterprises [11] Group 6 - The ongoing construction of a national unified market is a complex system project that requires continuous effort to eliminate barriers to resource flow and promote innovation [12] - The commitment to reform and the implementation of various measures will further enhance resource aggregation, stimulate innovation, upgrade industries, and support high-quality economic development in China [12]
血亏超4亿,募资缩水,护肤品败走!禾元生物“带伤”IPO
Nan Fang Du Shi Bao· 2025-07-14 11:29
Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the review for listing on the Sci-Tech Innovation Board, moving closer to its IPO after overcoming various challenges, including the expiration of financial documents [1] Fundraising and Financials - The company plans to raise approximately 2.4 billion yuan through the issuance of nearly 90 million shares, significantly lower than the previously planned 3.5 billion yuan [2][4] - The funds will be allocated to three main projects: 1.655 billion yuan for the construction of a recombinant human albumin industrialization base, over 600 million yuan for new drug research and development, and 100 million yuan for working capital [2][3] - The total investment for the recombinant human albumin industrialization base project is 1.909 billion yuan, with an expected annual production capacity of 120 tons of OsrHSA raw liquid [3] Revenue and Business Performance - The company has reported continuous losses over the past three years, with revenues of 13.4 million yuan in 2022, 24.3 million yuan in 2023, and an estimated 25.2 million yuan in 2024, while net profits were -122 million yuan, -187 million yuan, and -151 million yuan respectively [8][10] - The main source of revenue comes from pharmaceutical excipients and research reagents, with a small portion from beauty products, which accounted for less than 5% of total revenue [5][10] Legal Issues - The company is involved in a patent infringement lawsuit initiated by Ventria Bioscience, which claims that Heyuan's products infringe on its patents. The case has been ongoing since 2020, with a recent counter-suit filed by Heyuan against Ventria [12][13]
长江一号健康产业投资基金成立 出资额超34亿元
Jing Ji Guan Cha Wang· 2025-07-14 11:02
近日,据天眼查显示,湖北长江一号健康产业投资合伙企业(有限合伙)成立,执行事务合伙人为湖北 省长江新动能私募基金管理有限公司,出资额34.01亿人民币。合伙人信息显示,该基金由湖北长江产 业投资基金有限公司(份额99.97%)、湖北省长江新动能私募基金管理有限公司(份额0.03%)共同出 资。这两家公司均隶属于长江产业集团,是湖北省重要的国有资本投资平台。 (经济观察网 李强/文) 中研普华调研数据显示,截至2024年底,湖北省大健康领域高新技术企业数量突破1500家,较2020年增 长65%。在化学制药方面,人福医药(600079)、远大医药等企业在全国麻醉镇痛药、眼药水等细分市 场占据领先地位;在生物制药领域,武汉光谷生物城聚集了超过400家生物企业,在基因工程、疫苗研 发等领域形成了区域集群优势。 此外,根据在7月初长江产业集团召开"生物医药和大健康产业突破性发展"专题研讨会的有关消息,长 江一号健康产业投资基金也将承担组建长江产业集团生物医药与大健康产业专家委员会,依托专家力 量,深入研判行业动态、技术路线、并购标准等,为项目推进提供智力支持,提升产业发展的科学性和 前瞻性。 资料显示,长江产业集团成 ...
瞭望 | 穿越生物医药创新“死亡之谷”
Xin Hua She· 2025-07-14 10:37
文 |《瞭望》新闻周刊记者 刘巍巍 "实验室允许以高成本产出'概念件',在量产阶段,怎么以更低成本、更高效率生产出高合格率、高可 靠性的产品,至关重要。" "在这里,创业成本降到最低,我们只需要专注创新研发。""我们不需要在初期增加辅助人员,也不需 要扩建场地,企业的运营成本从千万级降至百万级。" 生物医药研发是"九死一生"的事。业内普遍认为,从前期研究到临床试验,最终获批上市,只有一成左 右的药物可以幸存下来。这个过程,往往持续10年甚至更长时间,耗费巨大的人力物力。 助力生物医药创新穿越"死亡之谷",生物医药中试平台在提升科技成果转化率、加快研发进度、降低创 业成本等方面发挥越来越显著的作用。 今年5月,工业和信息化部首批重点培育中试平台初步名单公示,其中药品33家、医疗器械7家,约占总 数的1/6。 生物医药中试需要解决从实验室到中试的工艺不确定性以及安全风险不确定性等,产业转化风险大与经 济价值突出并存,随着基因治疗、细胞药物等前沿技术发展,复杂性将进一步提升。 业内人士及专家表示,需聚焦关键共性问题,加大跨学科协同,加大投入和培育力度,推动中试平台加 速发展,为生物医药创新成果产业化应用提供有力支撑 ...
两家企业跻身“百强” 南京江北新区生物医药产业快速发展
Zheng Quan Shi Bao Wang· 2025-07-14 07:26
以先声药业为例,2024年,其创新药收入占比已超74%,近年来,集团持续加大研发投入,已实现上市 创新药数量10款。本月初,其申报的恩泽舒 (注射用苏维西塔单抗)获批上市。这款一类抗体新药, 也是我国首个取得铂耐药卵巢癌全人群适应症的靶向药,打破了该领域既往治疗选择有限的困局。 另一家入围企业健友股份,则是我国肝素原料药生产的龙头企业,其肝素制剂不仅畅销中国市场,更成 功打入欧美高端市场,全球化的优质客户群包括辉瑞、山德士、赛诺菲安万特等国际顶尖跨国制药巨 头。 如果说医药工业百强榜单看的是综合实力,不久前发布的《2025中国药品研发实力排行榜》系列榜单则 更注重"研值"。这系列"研值"榜中,南京江北新区生物医药谷有3家企业登榜:健友股份登上2025中国 化药研发实力排行榜,南京威凯尔登上2025中国医药CRO企业20强,药石科技(300725)登上2025中 国医药CDMO企业20强。 近日,2024年度中国医药工业主营业务收入前100位(医药工业百强)企业榜单揭晓。其中,南京有2家 企业入选——先声药业与健友股份(603707),均来自南京江北新区生物医药谷园区。 "中国医药工业百强"榜单集中度是衡量医药 ...